Radioactive One-Two punch takes on returning prostate cancer
NCT ID NCT07150715
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing two radioactive drugs, 225Ac-PSMA-617 and 177Lu-PSMA-617, combined with precise radiation therapy for prostate cancer that has returned and spread to a few spots in the body. The drugs target a protein on cancer cells and deliver radiation to kill them. The study will compare which drug works better with radiation to control the cancer and improve how long patients live without the disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radioactive drugs (225Ac-PSMA-617 or 177Lu-PSMA-617) plus stereotactic body radiotherapy
- What this could lead to
- If successful, this could offer a more effective way to control recurrent prostate cancer that has spread to a few sites, potentially delaying the need for hormone therapy.
- What could go wrong
- This is a phase II trial with only 107 participants, so results are preliminary. The radioactive drugs can cause side effects like low blood counts and dry mouth, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.